StemCells, Inc.
StemCells, Inc. company was founded in 1988 and is based in Palo Alto, California. StemCells, Inc. is a biopharmaceutical company. The Company is engaged in the discovery and development of cell-based therapeutics to treat damage to, or degeneration of, major organ systems. The Company has two product development programs: CNS Program, which is developing applications for its human neural stem cell and Liver Program, which is developing applications for its human liver engrafting cells. In addition, it is conducting preclinical work for spinal cord injury, myelin disorders and retinal disorders. In December 2008, the Company received authorization from the United States Food and Drug Administration (FDA) to initiate a Phase I clinical trial of its HuCNS-SC cells in a second indication, Pelizeaus-Merzbacher Disease (PMD), a fatal myelination disorder in the brain. In April 2009, StemCells, Inc. completed the acquisition of substantially all of the operating assets and liabilities of Stem Cell Sciences Plc.
Contact Details
Office Address
StemCells, Inc.
3155 Porter Drive
Palo Alto, CA, USA 94304-1213
Phone: (650) 475-3100
Fax: (650) 475-3101
Executives
Chief Exec. Officer
Mr. Martin M. McGlynn
Chief Financial Officer
Mr. Rodney K. B. Young
.webp)
.webp)
.webp)
.webp)
.webp)
